Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869089 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CC-10004 for Prurigo Nodularis
A Phase 2 study of Prurigo Nodularis, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00869089: Completed Phase 2 study of Prurigo Nodularis, sponsored by University Hospitals Cleveland Medical Center.
NCT00869089 is a Phase 2 study of Prurigo Nodularis that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 5 participants, below the 229-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00869089, a Phase 2 study of Prurigo Nodularis, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will include: * Study period up to 7 months. * Office visits monthly lasting approximately 1 hour. * Blood Draws. * Oral medication that is taken 2 times daily. * Photographs and biopsies if agreed.
Conditions Studied
Interventions
- DRUG CC-10004
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
What the finished NCT00869089 record still lists
NCT00869089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 229-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which CC-10004 is the first listed.
NCT00869089 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00869089 about?
NCT00869089 is a clinical study titled "Safety and Efficacy of CC-10004 for Prurigo Nodularis". This trial will include: * Study period up to 7 months. * Office visits monthly lasting approximately 1 hour. * Blood Draws. * Oral medication that is taken 2 times daily. * Photographs and biopsies if agreed.
What is the current status of trial NCT00869089?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-09. Estimated completion is 2011-01.
What conditions does trial NCT00869089 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT00869089?
The interventions under investigation include: CC-10004 (DRUG).
Who is sponsoring clinical trial NCT00869089?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00869089 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00869089's enrollment target sits among peer trials
5 15th of 14 the lowest of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Barzolvolimab in Patients With Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia